Introduction
Sepsis remains a major global healthcare challenge and a leading cause of critical illness and mortality. Characterised by life-threatening organ dysfunction resulting from a dysregulated host response to infection, sepsis requires early recognition, prompt treatment and coordinated multidisciplinary care.
According to global estimates cited in the 2026 Surviving Sepsis Campaign (SSC) guidelines, sepsis accounts for approximately 49 million cases and 13 million sepsis-related deaths annually. In addition to its immediate impact, sepsis can lead to long-term physical, cognitive and psychological complications among survivors.
The Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026, published in Intensive Care Medicine, provides updated evidence-based recommendations for the management of adult patients with sepsis and septic shock. Developed through collaboration between the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM), the guidelines address key aspects of sepsis care, from early identification and antimicrobial treatment to haemodynamic support, ICU management and post-hospital recovery.
The 2026 update places particular emphasis on strengthening sepsis quality improvement programmes, individualising treatment decisions, optimising antimicrobial use and improving outcomes beyond hospital discharge.
Understanding the 2026 Surviving Sepsis Campaign Guidelines
The 2026 guidelines were developed by a multidisciplinary committee of 69 experts representing 23 countries. The panel included clinicians and researchers from different healthcare disciplines, with 38% of members currently or previously practising in low- and middle-income countries.
The recommendations were developed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology, which evaluates the certainty of available evidence and the strength of clinical recommendations.
The updated guidelines cover six major areas:
- Screening and early management
- Infection management
- Haemodynamic management
- Respiratory support
- Additional and adjunctive therapies
- Goals of care, transitions of care and long-term outcomes
The document contains 129 numbered recommendations and good practice statements, providing guidance across the continuum of sepsis management.
Key Updates and Recommendations in the 2026 Guidelines
1. Strengthening Early Recognition and Sepsis Screening
Early identification remains one of the most important components of effective sepsis management. The 2026 guidelines recommend that hospitals and healthcare systems implement structured sepsis performance improvement programmes.
These programmes should include:
- Screening of acutely ill, high-risk patients.
- Standard operating procedures for sepsis treatment.
- Implementation of quality improvement strategies.
- Continuous monitoring of adherence to recommended clinical practices.
The guidelines also suggest implementing a ‘Code Sepsis’ or ‘Sepsis Huddle’ protocol. This involves a multidisciplinary team coming together at the patient’s bedside following a positive sepsis screen to facilitate rapid assessment and treatment.
Another important recommendation concerns the use of screening tools. For acutely ill hospitalised adults, the guidelines recommend NEWS, NEWS2, MEWS or SIRS over qSOFA as a single screening tool for sepsis.
Importantly, sepsis remains a clinical diagnosis and should not be confirmed or excluded using a single biomarker or diagnostic test.
2. Timely Antibiotic Administration and Antimicrobial Stewardship
Prompt administration of appropriate antimicrobial therapy remains central to sepsis management. However, the 2026 guidelines emphasise that the timing of treatment should be guided by the likelihood of infection and the severity of the patient’s condition.
The recommendations distinguish between patients with septic shock, confirmed or probable sepsis, and possible sepsis without shock.
Recommended timelines for antimicrobial administration:
- Possible, probable or definite septic shock: Antimicrobial therapy should be administered immediately, ideally within one hour of recognition.
- Probable or definite sepsis without shock: Antimicrobial therapy should also be initiated immediately, ideally within one hour.
- Possible sepsis without shock: A rapid assessment of infectious and non-infectious causes should be undertaken. If concern for infection persists, antimicrobial therapy should be administered within three hours of the initial suspicion of sepsis.
- Low likelihood of infection without shock: Antimicrobial therapy may be deferred while the patient is closely monitored.
The guidelines also emphasise the importance of obtaining blood cultures as soon as possible and ideally before antimicrobial administration, provided this does not delay treatment.
Antimicrobial stewardship remains equally important.
The updated recommendations highlight the need to continuously reassess patients receiving empirical antimicrobial therapy. If an alternative diagnosis is established or strongly suspected, unnecessary antimicrobial treatment should be discontinued.
When microbiological results and susceptibility profiles become available, clinicians are strongly recommended to de-escalate antimicrobial therapy. This involves discontinuing unnecessary agents or narrowing the antimicrobial spectrum based on the identified pathogen and its susceptibility.
The guidelines also support selected use of rapid pathogen-specific diagnostic tests to help guide treatment decisions, particularly in patients where local resistance patterns and clinical characteristics indicate a potential benefit.
3. Early Source Control to Manage Infection
Antimicrobial therapy alone may not be sufficient when an identifiable anatomical source of infection requires intervention.
The 2026 guidelines recommend rapid evaluation of patients with sepsis or septic shock for infections that require source control.
Source control involves procedures or interventions aimed at eliminating the source of infection, reducing pathogen burden or correcting anatomical abnormalities that contribute to persistent infection.
Examples include:
- Drainage of intra-abdominal or pelvic abscesses.
- Removal of infected medical devices or catheters.
- Surgical debridement of infected or necrotic tissue.
- Relief of biliary obstruction.
- Surgical intervention for gastrointestinal perforation.
For patients requiring source control, early intervention is suggested, ideally within six hours of diagnosis of sepsis or septic shock.
This recommendation highlights that timely antimicrobial administration and appropriate procedural intervention must work together to achieve effective infection management.
4. Individualised Fluid Resuscitation and Haemodynamic Management
Sepsis-induced hypoperfusion and septic shock can result in inadequate tissue oxygen delivery and progressive organ dysfunction. Fluid resuscitation and haemodynamic support are therefore essential components of treatment.
The 2026 guidelines recommend considering at least 30 mL/kg of intravenous crystalloid fluid within the first three hours for adults with sepsis-induced hypoperfusion or septic shock.
However, the guidelines emphasise that fluid administration should be individualised according to the patient’s clinical condition and underlying health factors.
Key recommendations include:
- Choice of fluids: Crystalloids are recommended as first-line fluids for resuscitation. Balanced crystalloids are suggested over normal saline for initial resuscitation in most patients.
- Fluid reassessment: Dynamic measures, such as response to passive leg raising or a fluid bolus, should be used to guide fluid administration.
- Lactate monitoring: Serial lactate measurements may help guide resuscitation in patients with elevated lactate or septic shock. Fluid administration should be individualised rather than continued solely until lactate levels normalise.
- Blood pressure targets: An initial mean arterial pressure (MAP) target of 65 mmHg is recommended for adults with septic shock. For patients aged 65 years or older, an initial MAP range of 60–65 mmHg is suggested.
- Vasopressor support: Norepinephrine remains the recommended first-line vasopressor for septic shock.
The guidelines also suggest initiating vasopressors through peripheral intravenous access when appropriate, rather than delaying treatment until central venous access is established.
These recommendations reinforce the importance of balancing adequate tissue perfusion with the risks associated with excessive fluid administration.
5. Respiratory Support and Management of Acute Respiratory Distress Syndrome
Respiratory complications, including acute hypoxaemic respiratory failure and acute respiratory distress syndrome (ARDS), are common in critically ill patients with sepsis.
The 2026 guidelines provide recommendations for assessing oxygenation and selecting appropriate respiratory support strategies.
Key recommendations include:
- Oxygenation should be assessed using pulse oximetry (SpO₂) or arterial blood gas measurements (SaO₂), alongside clinical examination.
- In patients with sepsis-associated ARDS, a low tidal volume ventilation strategy of approximately 6 mL/kg should be used rather than higher tidal volumes.
- Plateau pressure should be limited to 30 cm H₂O in patients with ARDS.
- Higher positive end-expiratory pressure (PEEP) is suggested for patients with moderate-to-severe ARDS.
- Prone ventilation for more than 12 hours daily is suggested for patients with moderate-to-severe ARDS.
The guidelines also recommend a tidal volume of 6–8 mL/kg of ideal body weight for patients with sepsis-associated hypoxaemic respiratory failure without ARDS.
These recommendations highlight the importance of lung-protective ventilation strategies to reduce the risk of further lung injury in critically ill patients.
6. Additional and Adjunctive Therapies
The 2026 guidelines address several supportive interventions that may be considered during the management of sepsis and septic shock.
Corticosteroids
Intravenous corticosteroids are suggested for adults with septic shock. This recommendation is consistent with the established role of corticosteroids in selected patients who continue to require vasopressor support.
Blood transfusion
A restrictive transfusion strategy is recommended over a liberal transfusion strategy in adults with sepsis or septic shock.
Nutritional support
Early enteral nutrition, preferably initiated within 72 hours, is suggested for patients with sepsis or septic shock.
Blood glucose management
Insulin therapy is recommended when blood glucose levels reach or exceed 180 mg/dL (10 mmol/L).
Renal replacement therapy
For patients with sepsis-associated acute kidney injury, renal replacement therapy should not be initiated in the absence of a definitive indication. When renal replacement therapy is required, either continuous or intermittent treatment may be used.
Other interventions
The guidelines suggest against the routine use of several adjunctive therapies for sepsis, including:
- Intravenous vitamin C.
- Intravenous immunoglobulins.
- Probiotics.
- Vitamin D as a treatment for sepsis.
- Blood purification therapies, including hemoperfusion, high-dose haemofiltration and plasma exchange.
These recommendations reinforce the importance of evidence-based treatment selection rather than routinely adding interventions without demonstrated clinical benefit.
7. Goals of Care and Shared Decision-Making
The updated guidelines recognise that sepsis management extends beyond immediate medical stabilisation.
Clinicians are encouraged to discuss prognosis and goals of care with patients and their families. The guidelines suggest addressing these discussions early, preferably within 72 hours.
Shared decision-making is particularly important when patients require prolonged critical care or have a high risk of long-term complications.
The recommendations also highlight the role of palliative care principles, when appropriate, in addressing symptoms, suffering and the needs of patients and their families.
8. Transitions of Care and Long-Term Recovery After Sepsis
One of the important aspects of the 2026 guidelines is the emphasis on recovery after hospitalisation.
Surviving sepsis does not necessarily mean a complete return to pre-illness health. Many patients experience persistent physical limitations, cognitive difficulties and psychological complications following discharge.
The guidelines recommend that healthcare systems establish strategies to support patients during the transition from intensive care to hospital wards and eventually back into the community.
Key recommendations include:
- Providing structured handovers during transitions between healthcare settings.
- Conducting comprehensive medication reconciliation at ICU and hospital discharge.
- Involving patients and families in discharge planning.
- Providing written and verbal information about sepsis, its treatment and potential long-term complications.
- Facilitating follow-up for physical, cognitive and emotional difficulties after discharge.
- Offering physical rehabilitation to appropriate survivors, particularly those who received prolonged invasive mechanical ventilation.
- Providing access to mental health support when required.
The guidelines also emphasise the importance of identifying social and economic support needs, including nutritional, financial and housing-related concerns.
This broader approach highlights the need to consider sepsis recovery as a continuum rather than limiting care to the period of hospitalisation.
What Do the 2026 Guidelines Mean for Clinical Practice?
The 2026 Surviving Sepsis Campaign guidelines reinforce the importance of a coordinated, evidence-based approach to managing sepsis and septic shock.
Several important priorities emerge from the updated recommendations:
1. Strengthening hospital-level preparedness: Structured screening programmes, standard operating procedures and multidisciplinary sepsis response protocols can help improve early recognition and treatment.
2. Balancing timely antimicrobial treatment with stewardship: Early antimicrobial administration remains essential in patients with a high likelihood of sepsis, while continuous reassessment and de-escalation help reduce unnecessary antimicrobial exposure.
3. Individualising supportive care: Fluid resuscitation, vasopressor use and respiratory support should be guided by the patient’s clinical condition rather than applied uniformly.
4. Prioritising infection source control: Identifying and eliminating the source of infection is an important part of achieving effective infection management.
5. Extending care beyond the ICU: Rehabilitation, patient education, medication review and long-term follow-up should form part of the overall sepsis care pathway.
For healthcare institutions, translating these recommendations into clinical protocols, staff education and quality improvement initiatives will be important for strengthening sepsis management.
Conclusion
The 2026 Surviving Sepsis Campaign guidelines provide a comprehensive framework for improving the management of sepsis and septic shock in adults. By addressing early recognition, antimicrobial therapy, source control, haemodynamic support, respiratory management and long-term recovery, the guidelines reinforce the need for coordinated care across the entire patient journey.
The continued emphasis on antimicrobial stewardship is particularly important in the context of increasing antimicrobial resistance. Timely treatment must be complemented by appropriate antimicrobial selection, microbiological assessment and de-escalation wherever clinically indicated.
Ultimately, improving sepsis outcomes requires more than individual treatment decisions. It calls for effective hospital systems, multidisciplinary collaboration, evidence-based interventions and sustained support for patients after discharge.
Reference
Prescott HC, Antonelli M, Alhazzani W, Møller MH, Alshamsi F, Azevedo LCP, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026. Intensive Care Medicine. 2026. DOI: https://doi.org/10.1007/s00134-026-08361-1
